Gaurav Premani, CFA

ASML Holding N.V.

ASML

A Near-Monopoly Lithography Franchise Powering Global Semiconductor Supply Chain with EUV Dominance and High-NA Optionality

Initiation coverage examining EUV leadership, High-NA optionality, DUV economics, installed-base services, competitive moat, semiconductor demand drivers, valuation summary, and key risks.

Tango Targets First-Line Pancreatic Cancer as Larger Combination Data Support Phase 3

Tango’s larger pancreatic-cancer dataset supports further investment in its oral drug combination. A planned first-line trial would expand the clinical and commercial opportunity, while research cuts concentrate resources on PRMT5 medicines. Drug supply, dose tolerability and evidence of added benefit will determine how effectively its capital supports development.

MacroGenics’ MGC026 Data Support Further Development, With Durability and Combination Benefits Still Unresolved

MacroGenics has evidence of MGC026 activity in heavily pretreated head-and-neck cancer, supporting further spending on a program whose global rights it retains. The planned first-line combination opens another development opportunity, but sustained responses and an acceptable safety profile are needed to strengthen its commercial and partnering prospects.

Helus Pharma Redesigns Its Anxiety Study as Pivotal Depression Data Approach

Helus is moving HLP004 into a larger, placebo-controlled monotherapy study while its lead depression drug approaches a Phase 3 readout. The revised anxiety program could establish a clearer efficacy signal, but near-term shareholder value depends more heavily on HLP003 and the cost of completing its development.

Roivant’s Uveitis Results Give Brepocitinib a Stronger Route to a Second Market

Two positive Phase 3 studies strengthen the case for expanding brepocitinib beyond its newly approved use in dermatomyositis. Durable disease control after steroid withdrawal supports a commercial opportunity in eye inflammation, although the higher studied dose, safety profile and established alternatives will influence its reach.

EyePoint’s Second Wet-AMD Failure Shifts Its Funding Priorities to Diabetic Eye Disease

EyePoint is cutting its workforce after DURAVYU missed another pivotal vision endpoint. Its diabetic macular edema program remains active, but the earlier supporting study differs materially from the ongoing trials. The investment assessment now depends on stronger clinical evidence and a clearer funding plan.

Vir’s Gilead Agreement Adds a Different Funding Model to Its Cancer Pipeline

Gilead’s collaboration gives Vir another route to earn returns from its licensed cancer-drug technology, with the partner taking responsibility for later development. The immediate funding is modest beside Vir’s existing resources, but the allocation of costs and commercial rights differs from its Astellas partnership.

Two Phase 3 Wins Give Bristol Myers New Options Beyond Its Current Portfolio

Bristol Myers Squibb has reported successful pivotal trials in pulmonary fibrosis and radiopharmaceutical oncology. The readouts strengthen two future-growth programs, including the lead asset from its $4.1 billion RayzeBio acquisition, although the data disclosed so far are insufficient to estimate their commercial value.

Viatris’s Pacira Deal Buys Established Pain Medicines, but Growth Must Justify the Price

Viatris’s $1.65 billion cash offer adds two marketed non-opioid pain medicines and a U.S. commercial platform. The investment case depends on product durability, international expansion and cash returns, with Pacira’s debt, recent divestiture and adjusted earnings complicating a simple acquisition-multiple comparison.

Vaxcyte’s Phase 3 Success Advances a Broader Vaccine Toward Its Next Regulatory Tests

VAX-31 passed every primary endpoint in its pivotal adult trial, supporting a broader pneumococcal vaccine profile. Individual comparator results, remaining manufacturing studies and rising development spending will shape the path to Vaxcyte’s planned 2028 filing and eventual commercial opportunity.

Jaypirca Moves Into First-Line CLL, Expanding Lilly’s Oncology Opportunity in a Crowded Market

FDA approval brings Lilly’s noncovalent BTK inhibitor into initial treatment for eligible patients with chronic lymphocytic leukemia. The commercial opportunity now extends earlier in the disease course, while competing targeted therapies, treatment duration and tolerability will determine how much of that opportunity becomes revenue.

Surrozen’s FDA Clearance Unlocks $95 Million and a Clinical Test

SZN-8141 can now enter the clinic just as Merck has validated Wnt activation in diabetic macular edema. A pre-committed $95.1 million financing gives Surrozen capital to test whether combining Wnt activation with VEGF inhibition can improve on either mechanism alone.

Foghorn Lost Its Lilly Partnership, but the 40% Workforce Cut Changes the Valuation Math

Foghorn Therapeutics has discontinued FHD-909 and effectively ended a collaboration that brought in $380 million of upfront cash and equity from Lilly. The clinical failure removes its most advanced partnered asset, but a 40% workforce reduction extends cash runway into the second half of 2029 and leaves the company with $167.6 million of June cash and securities against a market value of roughly $200 million.